Osteoporosis Risk Assessment Instrument (ORAI)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk0–8
- High risk9–26
The Osteoporosis Risk Assessment Instrument (ORAI) calculates classifying inflammatory arthritides and monitoring longitudinal autoimmune disease activity. Key inputs include age. Scores guide initiating or optimizing disease-modifying antirheumatic drugs (DMARDs) or targeted biologic therapies. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Identifies women at risk for osteoporosis and recommends bone densitometry. Uses age, weight, and current estrogen use to stratify risk in postmenopausal women.
Clinical Indication
The Osteoporosis Risk Assessment Instrument (ORAI) is indicated for bedside clinical practice to support Identifies women at risk for osteoporosis and recommends bone densitometry. Uses age, weight, and current estrogen use to stratify risk in postmenopausal women.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with inflammatory arthritis, systemic lupus erythematosus, systemic vasculitis, or autoimmune connective tissue disorders. Clinical application is indicated across Rheumatology clinics, connective tissue disease units, and academic medical centers.
Limitations & Contraindications
Elevated erythrocyte sedimentation rate (ESR) and CRP are non-specific acute phase reactants that can reflect occult systemic infection.
Clinical Pearls & Action Plan
Serological autoantibody testing must strictly correlate with inflammatory joint patterns and objective synovial pathology. Guideline pearl: Sensitivity 93.3%, specificity 46.4% at cutoff of 9 points.
ORAI Score = Age points + Weight points + Estrogen use points
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | string | Yes | Age range of the patient |
| weight | string | Yes | Weight category of the patient |
| current_estrogen_use | string | Yes | Is the patient currently using estrogen (hormone replacement therapy)? |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–8 | Low risk | Bone densitometry may not be needed |
| 9–26 | High risk | Consider bone densitometry |
Evidence-Based References (EBM)
- Cadarette SM, Jaglal SB, Kreiger N, McIsaac WJ, Darlington GA, Tu JV. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 2000 May 2;162(9):1289-94.
- El Maghraoui A, Habbassi A, Ghazi M, Achemlal L, Mounach A, Nouijai A, et al. Validation and comparative evaluation of four osteoporosis risk assessment tools in Moroccan menopausal women. Arch Osteoporos. 2006 Dec;1(1-2):35-42. doi: 10.1007/s11657-006-0006-1.DOI: 10.1007/s11657-006-0006-1
- Rubin KH, Abrahamsen B, Friis-Holmberg T, Hjelmborg JV, Bech M, Hermann AP, et al. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone. 2013 Sep;56(1):16-22. doi: 10.1016/j.bone.2013.05.002.DOI: 10.1016/j.bone.2013.05.002